Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · IEX Real-Time Price · USD
1.240
-0.020 (-1.59%)
At close: Mar 28, 2024, 4:00 PM
1.270
+0.030 (2.42%)
After-hours: Mar 28, 2024, 7:51 PM EDT

Company Description

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.

The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases.

The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics, Inc.
Aclaris Therapeutics logo
Country United States
Founded 2012
IPO Date Oct 7, 2015
Industry Diagnostics & Research
Sector Healthcare
Employees 86
CEO Dr. Neal S. Walker D.O., M.D.

Contact Details

Address:
701 Lee Road, Suite 103
Wayne, Pennsylvania 19087
United States
Phone 484-324-7933
Website aclaristx.com

Stock Details

Ticker Symbol ACRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001557746
CUSIP Number 00461U105
ISIN Number US00461U1051
Employer ID 46-0571712
SIC Code 2834

Key Executives

Name Position
Dr. Neal S. Walker D.O., M.D. Co-Founder, President, Chairman and Interim Chief Executive Officer
Dr. Joseph Monahan Ph.D. Chief Scientific Officer
Kevin Balthaser Chief Financial Officer
Matthew Rothman J.D. General Counsel and Corporate Secretary
Dr. Jon Jacobsen Ph.D. Senior Vice President of Chemistry
James Loerop Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 19, 2024 8-K Current Report
Feb 27, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals